Metabolism of halothane was studied in nine children receiving daily halothane anaesthetics (from 10 up to a maximum of 31) over periods of two to seven weeks. Serum bromide concentrations never exceeded 3.5 mmolll, a concentration below the toxic threshold. Repeated halothane anaesthetics at short intervals did not induce the reductive metabolism of halothane as assessed by 2-chloro-1,1,1-trifluoroethane (CTF) in the expired breath. One patient developed viral hepatitis A during the course of anaesthetic administration; this patient was the only one whose serum bromide concentrations fell substantially and whose exhaled CTF concentration increased as more anaesthetics were administered. J
metabolism. Thus, toxic metabolites may be formed in greater amounts during repeated anaesthetics, with increased risk of liver injury. 7 Whether halothane does induce its own metabolism is unknown. In adults, halothane is rarely given repeatedly over a short interval due to the risk of liver injury, so there is little opportunity to investigate this question. Halothane hepatitis is, however, very rare in children, even when repeated anaesthetics are given. 9 • 11 Thus, when we were approached by radiotherapists who were having difficulty keeping young children still on a daily basis, even with heavy sedation, we elected to use halothane anaesthesia. This provided the opportunity to investigate halothane metabolism during repeated anaesthetics in a group of child patients.
A further potential hazard of repeated halothane anaesthetics has received little attention. Bromide is a major metabolite of halothane, plasma concentrations reaching 1-2 mmolll after a single anaesthetic in adults. 12 Bromide is excreted very slowly from the body, its half-life in adults ranging from less than two to over four weeks. 13 • 14 Symptoms of bromide intoxication can occur at serum bromide concentrations in the range 6-12 mmol/l and are generally observed when concentrations exceed 12 mmol/l. 15 It is possible that repeated halothane anaesthetics could lead to sufficient accumulation of bromide for toxic symptoms to develop. These symptoms include poor memory, apathy, anorexia and drowsinesssymptoms whose cause might be difficult to identify in a child undergoing frequent anaesthetics for surgery or other procedures. We aimed therefore to determine the serum bromide concentrations which could occur during repeated halothane anaesthetics.
METHODS
This study was approved by the Flinders Medical Centre Clinical Investigation Committee. Nine children requiring repeated halothane anaesthetics for radiotherapy were studied. Patient details are given in Table 1 .
Anaesthetics were administered daily for two to seven weeks, Monday to Friday, except on public holidays and during periods when the patient's condition precluded anaesthesia. All children had previously been exposed to halothane on two or more occasions but not for at least one week prior to the commencement of the trial. All anaesthetics were induced without premedication but with a parent present, using N 2 0:02,5:2 with 2-3070 halothane via an Ayre's T -piece with the mask away from the face, and when the pupils were central, after 3-4 minutes, the child was intubated and maintained spon taneously breathing on 1.0-1.2070 halothane according to needs. The anaesthetics lasted for 25-30 minutes.
Every Friday during the course of radiotherapy, a blood sample was taken soon after induction for measurement of serum bromide concentration and liver function tests. When possible, blood samples were also taken during the first anaesthetic which was given to assess the radiation fields and in some cases, occasional samples were taken after the radiotherapy course was completed.
On each Monday and Friday that an anaesthetic was administered, breath samples were collected for measurement of the volatile metabolite of halothane, 2-chloro-1, 1,1trifluoroethane (CTF). Breath samples were collected via a needle inserted into the distal end of the endotracheal tube and the fresh gas flow entered the T -piece more than 10 cm from the endotracheal tube. The samples were always collected during the last anaesthetic in the series, even if this was not a Monday or Friday, and in some cases, samples were obtained during the first anaesthetic. If for any reason an anaesthetic was not administered on a Monday or Friday during the course of treatment, samples were collected during the next anaesthetic administered. Three breath samples were collected on each occasion, approximately equally spaced between 10 and 25 minutes after induction. When it was desired to collect a breath sample, the fresh gas flow was turned off, allowing the patient to rebreathe the same gas so that it could approach equilibrium with within a single patient) as well in multiple series (Le. within a group of patients). It was used to determine whether CTF concentrations increased or decreased as anaesthetics continue to be administered, both in each individual patient and in the patient group as a whole. When testing results of individual patients for trend, Bonferroni's correction for multiple tests was applied to maintain overall Type I error at 0.05. As there were nine patients, this led to rejecting the null hypothesis of no trend for any one patient if the 'P value' was less than 0.006. As some patterns of altered CTF exhalation may not lead to a marked trend, we also compared CTF exhalation during the first halothane anaesthetic with the mean of all subsequent measurements using the Wilcoxon signed rank test. While our prime interest was to look for increasing halothane metabolism during repeated anaesthetics, we also considered it possible that metabolism would decrease; therefore, all tests were two-tailed.
RESULTS

Liver junction tests
Patients received from 10 to 31 anaesthetics during the study period. The only patient to exhibit abnormal liver function tests was patient 8. After six weeks of anaesthetics (during which 26 anaesthetics were administered) serum aspartate aminotransferase (AST) rose to 163 VII and serum alanine aminotransferase (A LT) to 121 VII. Serum enzymes continued to rise, AST reaching 1405 and ALT 1060 after seven weeks of anaesthetics (a total of 31 anaesthetics, each of duration approximately 30 minutes). No clinical signs of liver dysfunction were apparent, and a serological diagnosis of viral hepatitis A was made on two occasions. Nevertheless, it was decided to discontinue halothane administration. Serum enzymes returned to normal within one month, no clinical signs of liver injury being apparent at any time.
Serum bromide concentrations
Serum bromide concentrations in some patients were already elevated before the first blood sample was taken, due to the prior administration of anaesthetics. During the course of anaesthetic administrations, maximum serum bromide concentrations ranged from 1.05 to 3.47 mmolll. In some patients, serum bromide concentrations appeared to reach a plateau and did not increase further, even though more anaesthetics were administered. However, in other patients, bromide levels did not reach a plateau by the end of the series of anaesthetics. Serum bromide concentrations of three patients are shown in Figure 1 . Patient 8 was the only patient in whom serum bromide concentrations fell substantially while anaesthetics continued to be administered. In five patients, serum bromide concentrations were monitored for up to ten weeks after the last halothane administration. The rate of decline was consistent with a half-life of two to four weeks similar to that in adults. '
CTF exhalation
CTF concentrations were similar in the three breath samples taken during any anaesthetic administration. Therefore, the mean value of the three samples was used as an index of CTF exhalation. Exhaled CTF concentrations of three patients are shown in Figure 2 .
CTF exhalation by two patients (patients 6 and 9) was higher than by the other patients and showed great fluctuations, concentrations ranging from 1.5 to over 20 ppm. We could not identify any cause for this great variation. Most patients, however, exhaled relatively constant amounts, in the range 0.2-2 ppm. The only patient in whom CTF exhalation showed a significant trend was patient 8, who tended to exhale higher concentrations as more anaesthetics were given. For the group of patients as a whole, there was a significant trend towards increasing CTF exhalation (P=0.03). However, as more samples were collected from patient 8 than from the others, this patient had a large influence on the overall result. It was felt that the liver dysfunction may have affected halothane metabolism in patient 8; therefore, the data were re-analysed, with 7) . This was supported by the finding of no difference between CTF exhalation during the first anaesthetic and the mean of all subsequent CTF measurements (P>O.2). Data from only six patients were used in this comparison, as three patients had had halothane anaesthetics during which CTF was not measured in the two weeks preceding the study.
DISCUSSION
In this study, nine children received from 10 to 31 halothane anaesthetics over periods of from two to seven weeks. Eight of the patients showed no evidence of liver dysfunction, while one developed viral hepatitis A. It has been suggested that anaesthesia may precipitate viral hepatitis by depressing the immune system. [8 In the present case, it is impossible to determine whether halothane was a contributing factor.
Serum bromide concentration in all patients remained below the range (6-12 mmolll) in which toxic effects have been reported. Although in some patients serum bromide was still increasing at the end of the series of anaesthetics, it remained well below the toxic threshold. Thus, there appears to be little risk of bromide intoxication in children receiving repeated halothane anaesthetics of short duration.
~ith the exception of patient 8, there was no eVidence that CTF exhalation increased or decreased as additional halothane anaesthetics were administered. CTF is a product of the reductive pathway. of halothane metabolism . Thus, mechanisms other than induction of its own reductive metabolism must be sought to explain the role of repeated halothane anaesthetics in halothane hepatitis. It is of interest that two children in this study at times ex~ale~ CTF in concentrations above 20 ppm, which IS 10-50 times higher than reported in adults. [9,20 These children did not, however, show ~ny signs of liver injury. Although ~eductlv~ halothane metabolism is clearly Illvolved III causing liver injury in the hypoxic rat model,2,3,2[ this study suggests that extensive reductive halothane metabolism, even on a ?~m?er of occasions, is not necessarily IllJunous to human liver. It is possible of course that adults or perhaps only rare individuals could respond differently. The two patients whose CTF exhalation was highest were both females under 30 months old. We have, however, measured CTF exhalation in three other girls, aged 2 to 24 months, undergoing single halothane anaesthetics, and found it to be the normal range (i.e. about 0.2-3 ppm).
Patient 8, who developed subclinical viral hepatitis, showed a different pattern of halothane metabolism to the other patients. This patient was the only one whose serum bromide concentration, an index of oxidative halothane metabolism, declined substantially while anaesthetics were still being administered, and was the only one to show a trend towards increasing reductive metabolism of halothane. These changes became evident approximately two weeks before serum enzymes were elevated. The decrease in serum bromide is presumably due to impaired ability of hepatocytes to metabolise halothane. It might be thought that reductive metabolism of halothane should also decrease. However, reductive metabolism is increased by hepatic hypoxia, and it may be that physiological changes in the liver are a more important factor than the activity of the drug metabolising enzymes.
